Glenmark Pharma Q3

Jump to

Glenmark Pharma Q3 net beats forecast, up 1.5% to Rs 216 cr

Year-on-year consolidated net profit increased to Rs 216.2 crore from Rs 213 crore and revenue rose to Rs 1,601.2 crore from Rs 1,382 crore. Analysts had expected a 14 percent degrowth in bottomline at Rs 184 crore and 13.2 percent growth in topline at Rs 1,565 crore for the quarter.
Glenmark Q3 PAT seen down 14% to Rs 184 cr on high base

Revenues are seen going up 13.2 percent to Rs 1,565 crore in the quarter ended December 2013 from Rs 1,382 crore in a year ago period.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Glenmark Pharma Q3

Glenmark Pharma Q3 net beats forecast, up 1.5% to Rs 216 cr

Glenmark Q3 PAT seen down 14% to Rs 184 cr on high base